Secondary Logo

Journal Logo

A Human Recombinant IL-7/HGFα Hybrid Cytokine Enhances T-Cell Reconstitution in Mice After Syngeneic Bone Marrow Transplantation

Lai, Laijun1,2,3; Jin, Jingjun1; Hodio, Jennifer1; Goldschneider, Irving1

doi: 10.1097/TP.0b013e318228d766
Basic and Experimental Research
Free
SDC

Background. T-cell regeneration after bone marrow transplantation (BMT) is often slow and incomplete. Therefore, the enhancement of T-cell reconstitution after BMT is required. We have previously described a naturally occurring hybrid cytokine consisting of interleukin (IL)-7 and the β-chain of hepatocyte growth factor (HGF) that had lymphopoietic stimulatory activity in vitro. We have also reported that a murine recombinant (r) IL-7/HGFβ protein significantly enhances T-cell regeneration in mice after BMT.

Methods. To determine whether a human form of rIL-7/HGFβ has similar effects as the murine form, we have cloned and expressed the human IL-7 and HGFβ genes to produce a single-chain hrIL-7/HGFβ protein. We have also cloned and expressed a human form of hybrid cytokine containing IL-7 and the α-chain of HGF (HGFα) (hrIL-7/HGFα). We then determined their ability to enhance T-cell reconstitution in mice after BMT.

Results. We found that hrIL-7/HGFα had higher in vitro and in vivo thymocyte-stimulatory activities than did the hrIL-7/HGFβ. Therefore, we focused on the functional properties of hrIL-7/HGFα and showed that administration of hrIL-7/HGFα significantly enhanced thymopoiesis in mice after syngeneic BMT by increasing the numbers of thymocytes, early thymocyte progenitors, and thymic epithelial cells. hrIL-7/HGFα cross-linked the IL-7 and HGF receptors on thymocytes, and the in vivo thymocyte-stimulatory activity was mediated by both receptors. Consequently, hrIL-7/HGFα treatment significantly increased the numbers of total and naïve T cells in the periphery.

Conclusion. In vivo administration of hrIL-7/HGFα efficiently restores thymopoiesis and naïve T-cell reconstitution in mice after syngeneic BMT.

SUPPLEMENTAL DIGITAL CONTENT IS AVAILABLE IN THE TEXT.

1 Department of Immunology, School of Medicine, University of Connecticut Health Center, Farmington, CT.

2 Stem Cell Institute, University of Connecticut, Farmington, CT.

This work was supported in part by a grant from the Connecticut Stem Cell Research Program (08-SCA-UCHC-009) (L.L.).

L.L. and I.G. are named as inventors in a provisional patent application.

All other authors declare no conflicts of interest.

3 Address correspondence to: Laijun Lai, M.D., Department of Immunology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030.

E-mail: llai@neuron.uchc.edu

L.L. designed the research; L.L., J.J., and J.H. performed experiments; L.L., J.J., and I.G. analyzed data; and L.L. and I.G. wrote the manuscript.

Supplemental digital content (SDC) is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal's Web site (www.transplantjournal.com).

Received 31 October 2011. Revision requested 19 November 2011.

Accepted 10 June 2011.

Bone marrow transplantation (BMT) is often followed by a prolonged period of T-cell deficiency, which contributes to increased morbidity and mortality from common and opportunistic infections and increased incidence or relapse of cancers (1, 2). We have identified a unique mouse bone marrow (BM) stromal cell-derived hybrid cytokine, consisting of interleukin (IL)-7 and hepatocyte growth factor (HGF) β (IL-7/HGFβ), that selectively stimulates the proliferation and subsequent differentiation of common lymphoid progenitors, early B-lineage cells, and thymocytes (3–5). We have cloned, constructed, and expressed the murine IL-7/HGFβ gene to generate a single-chain rIL-7/HGFβ protein that has the aforementioned functional properties and also stimulates the in vitro expansion of day 12 spleen colony-forming units (6). We have also shown that the in vivo administration of rIL-7/HGFβ supports the rapid and complete regeneration of the thymus and efficiently reconstitutes the pool of naïve T cells in mice after BMT (7). These observations raised the possibility that rIL-7/HGFβ may have potential clinical utility. However, because murine rIL-7 does not efficiently stimulate human lymphoid cells (8) and would be perceived as a foreign antigen in the human host, it was unlikely that it would be useful for this purpose. Therefore, we set out in this study to develop a human form of the hybrid cytokine.

We have cloned and expressed a human form of rIL-7/HGFβ protein containing human IL-7 and HGFβ. As HGF is a heterodimeric protein consisting of an α- and β-chain (9, 10), we have also constructed an hrIL-7/HGFα hybrid cytokine, using the human IL-7 and the NK1 naturally occurring HGFα splice variant (11). Because hrIL-7 and hrHGF are active in the mouse (8), we were able to conduct preclinical studies of these human hybrid cytokines in this specie. However, somewhat surprisingly, the hrIL-7/HGFα protein was more active than the hrIL-7/HGFβ protein in stimulating thymocyte proliferation in vitro and in vivo. Therefore, we focused on the functional properties of hrIL-7/HGFα in stimulating thymopoiesis after BMT in the mouse. The results demonstrated that, when administered systemically, hrIL-7/HGFα restored thymopoiesis rapidly and completely after syngeneic BMT, and the stimulatory activity was inhibited by both neutralizing antibodies against the IL-7 and HGF receptors. Confocal microscopy revealed that hrIL-7/HGFα induced the co-localization of the IL-7 and HGF receptors on the subsets of thymocytes that co-expressed both receptors. Furthermore, unlike equimolar amounts of hrIL-7 or hrHGFα used individually or in mixtures, hrIL-7/HGFα significantly increased the numbers of early thymocyte progenitors (ETPs) and thymic epithelial cells (TECs) in the BMT recipients. In addition, hrIL-7/HGFα selectively supported the rapid reconstitution of T-cell receptor (TCR) Vβ diverse naïve T cells in the periphery. In each of these functions, hrIL-7/HGFα was superior to its individual hrIL-7 and hrHGFα components. Therefore, hrIL-7/HGFα might be useful clinically in preventing and correcting post-BMT T-cell deficiency.

Back to Top | Article Outline

RESULTS

Expression and Purification of Human Single-Chain rIL-7/HGFα (NK1) Proteins

We have successfully constructed human IL-7/HGFα genes in which the IL-7 and HGFα (NK1) genes were connected by a flexible linker. The IL-7/HGFα gene was transfected and expressed in a mammalian expression system, and the hrIL-7/HGFα protein was then purified until only a single major band appeared in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Fig. 1). The purified protein was confirmed by Western Blotting using antibodies against human IL-7 and HGF (Fig. 1). The actual molecular weight (MW) of the rIL-7/HGFα was higher than the predicted MW, suggesting that the recombinant protein was glycosylated. Our initial experiments showed that equivalent molar amounts of hrIL-7/HGFα had a mean 11-fold higher in vitro thymocyte-stimulatory activity (data not shown) and about 1.5-fold higher in vivo thymocyte-stimulatory activity than did hrIL-7/HGFβ (Fig. 2A). Therefore, we have focused on the functional properties of the hrIL-7/HGFα in the following experiments, using the individual hrIL-7 and hrHGFα cytokines from the same expression system as controls.

FIGURE 1.

FIGURE 1.

FIGURE 2.

FIGURE 2.

Back to Top | Article Outline

hrIL-7/HGFα Enhances the Number of Thymocytes After BMT

To evaluate whether hrIL-7/HGFα affects thymopoiesis in vivo after BMT, lethally irradiated C57BL/6 mice were injected intravenously (IV) with T-cell–depleted (TCD)-BM from congeneic mice (B6 Ly 5.1) and intraperitoneally with different doses of hrIL-7/HGFα (2.5, 5, 10, 15, 20, and 40 μg/injection) and equimolar doses of hrIL-7, hrHGFα, or control vehicle (phosphate-buffered saline [PBS]) at 2-day intervals between days 1 and 25. The total numbers of donor-origin thymocytes (>87%) were analyzed on day 30. As shown in Figure 2(B), roughly parallel dose-response curves were observed between hrIL-7/HGFα and hrIL-7 when the results were plotted as a function of equivalent MW (∼2.5:1). However, the amplitude of the responses differed, such that, at optimal equimolar doses (15 μg vs. 6 μg), hrIL-7/HGFα was about two times more effective at enhancing thymic cellularity than was hrIL-7. In contrast, hrHGFα alone had no effect. Analysis of thymocyte subsets showed that both hrIL-7/HGFα and hrIL-7 at optimal doses (15 and 6 μg/injection, respectively) increased all thymocyte subsets, including CD4 and CD8 double-negative (DN), double-positive, and CD4 or CD8 single-positive (SP) cells (Fig. 2C). Furthermore, the increase in thymocyte numbers in the hrIL-7/HGFα-treated BMT recipients was maintained for at least 3 months (see Figure 1, SDC 1,http://links.lww.com/TP/A471).

To determine whether both the IL-7 and HGF receptors are involved in the in vivo effects of hrIL-7/HGFα, a cohort of hrIL-7/HGFα-treated BMT recipients were injected with neutralizing anti-IL-7Rα and anti-c-Met antibodies, or isotype control antibodies. As shown in Figure 2(D), both anti-IL-7Rα or anti-c-Met antibodies used alone significantly inhibited the in vivo thymocyte-stimulatory effects of hrIL-7/HGFα, and the combination of anti-IL-7Rα and anti-c-Met antibodies was more effective than either antibody alone. The data suggest that the in vivo effects of hrIL-7/HGFα are mediated through both the IL-7 and the HGF receptors.

Back to Top | Article Outline

hrIL-7/HGFα Increases the Number of ETPs After BMT

It has been reported that only a minor lin IL-7Rαc-Kit+CD44+CD25 subset of DN1 thymocytes, termed ETPs, contain canonical thymocyte precursors (12–14). Therefore, we determined whether hrIL-7/ HGFα influences the numbers of ETPs after BMT. As shown in Figure 3(A), the absolute numbers of donor-origin ETPs in the hrIL-7/HGFα-treated mice was increased approximately 3-fold above normal levels and 6- to 10-fold above those in the PBS-, hrIL-7-, and hrHGFα-treated mice.

FIGURE 3.

FIGURE 3.

Back to Top | Article Outline

rIL-7/HGFα Increases the Number of TECs After BMT

T-cell development in the thymus is supported by the thymic microenvironment, of which TECs are the major components (15, 16). When the numbers of total TECs (CD45 EpCAM+MHC II+) were determined on day 30 after BMT, the PBS-, rIL-7-, and rHGFα-treated mice had slightly reduced numbers of TECs when compared with those in non-BMT control mice (Fig. 3B). In contrast, the administration of hrIL-7/HGFα increased the number of TECs by approximately 2-fold above normal, and both cortical (c) TECs (CD45EpCAM+MHC II+Ly51+) and medullary (m) TECs (CD45EpCAM+MHC II+Ly51) were affected (Fig. 3B).

Back to Top | Article Outline

hrIL-7/HGFα Increases the Numbers of Naïve T Cells in the Periphery

Naïve CD4 SP and CD8 SP T cells, newly derived from the thymus, exhibit a CD62LhiCD44lo phenotype (17, 18). As shown in Figure 4, the numbers of total and naïve donor-origin CD4+ and CD8+ T cells were increased significantly above normal levels in the hrIL-7/HGFα-treated BMT mice (Fig. 4). Treatment with hrIL-7 alone or together with hrHGFα also increased total and naïve splenic T cell numbers, but only about half as well as did hrIL-7/HGFα.

FIGURE 4.

FIGURE 4.

Back to Top | Article Outline

hrIL-7/HGFα-Treated BMT Mice Have a Diverse TCR Repertoire

In these experiments, we compared the TCR Vβ usage of donor-derived peripheral T cells in the blood of hrIL-7/HGFα-treated BMT mice with that of normal control mice. As shown in Supplemental Figure 2 (see SDC 1,http://links.lww.com/TP/A471), the TCR Vβ usage was indistinguishable between the two cohorts of mice. This suggested that the precursors of these newly formed T cells had undergone normal positive and negative selection in the regenerating thymus.

Back to Top | Article Outline

hrIL-7/HGFα Induces Receptor Colocalization on Thymocytes That Co-express the IL-7Rα and c-Met Receptors

We previously reported that both the IL-7 and HGF receptors from rIL-7/HGFβ-stimulated thymocytes were co-immunoprecipitated by anti-IL-7Rα antibody (7), suggesting that rIL-7/HGFβ physically cross-links c-Met and IL-7Rα on the surface of thymocytes. The results in Figure 5 show that c-Met and IL-7Rα exist as aggregates that have undergone patching and capping on dual receptor-expressing thymocytes that have been stimulated with hrIL-7/HGFα. However, receptor aggregates do not form after treatment of such cells with hrIL-7 and hrHGFα. These data also suggest that hrIL-7/HGFα cross-links the IL-7 and HGF receptors on dual-expressing thymocytes and may induce functionally unique juxtacrine signaling (6).

FIGURE 5.

FIGURE 5.

Back to Top | Article Outline

DISCUSSION

We have demonstrated that hrIL-7/HGFα treatment is quantitatively superior to hrIL-7 and hrHGFα in increasing the number of thymocytes and naïve T cells in lethally irradiated mice after syngeneic BMT. In addition, hrIL-7/HGFα treatment differs qualitatively from hrIL-7 and hrHGFα treatment by cross-linking the IL-7 and HGF receptors on the thymocyte subsets that co-express both receptors and by markedly increasing the numbers of TECs and ETPs. Consequently, hrIL-7/HGFα treatment significantly increased the numbers of total and naïve T cells in the spleen of BMT mice. Importantly, these donor-origin T cells (presumably recent thymic emigrants) exhibited a normal pattern of TCR Vβ usage. These results closely resemble those that we observed when BMT mice were treated with the murine form of rIL-7/HGFβ (7).

Our results also demonstrated that the hrIL-7/HGFα hybrid cytokine was more potent than hrIL-7/HGFβ in stimulating thymocyte proliferation in vitro and in vivo. This may be because of the HGFα chain binds and activates c-Met more efficiently than can the HGFβ chain (9, 10). It is also possible that the hrIL-7 component of hrIL-7/HGFα can more avidly bind to the IL-7 receptor than can its counterpart in hrIL-7/HGFβ.

In retrospect, our results are not entirely surprising, as rHGF is known to protect TECs against injury caused by irradiation or graft-versus-host disease (19) and can up-regulate the production of endogenous IL-7 in the regenerating thymus, presumably secondary to its effects on TECs (20). Yet, like Imado et al. (19), we observed that rHGFα alone did not detectably enhance thymopoiesis after syngeneic BMT. These results suggest that, despite the agonistic effects of HGFα in vivo (10, 21, 22), the physical linkage of IL-7 to HGFα in the hrIL-7/HGFα molecule is required to effectively stimulate thymopoiesis after BMT. Indeed, we have shown that hrIL-7/HGFα stimulation induces co-localization of the IL-7 and HGF receptors on co-expressing thymocytes, raising the possibility that such cross-linking may cause juxtacrine receptor interactions, downstream signal cross-talk, and unique functional readouts, as shown for common lymphocyte progenitors and prepro-B cells (see Ref. 6 and our unpublished observations). We have further confirmed the involvement of both the IL-7 and HGF receptors by partial inhibition of in vivo thymocyte-stimulatory activity with either anti-IL-7Rα or anti-c-Met antibody, and the more complete inhibition by a combination of anti-IL-7Rα and anti-c-Met antibodies.

Yet, we and others have shown that although all thymocyte subsets (including ETPs) express c-Met, only the DN and SP thymocyte subsets express the IL-7Rα-chain of the high affinity IL-7R (7, 23, 24). Therefore, it is possible that rIL-7 stimulates only those thymocytes that express the IL-7 receptor, whereas hrIL-7/HGFα stimulates all thymocytes, including those that express c-Met, but not IL-7Rα by cross-linking c-Met with the γc chain or other receptor(s), such as c-kit (25). This may also be true for TECs, although their increased numbers of TECs may be secondary to their interaction with regenerating thymocytes (26, 27). It is also possible that the increased numbers of ETPs seen in the hrIL-7/HGFα-treated thymus is caused by the increased generation or migration of thymocyte progenitors in/from the BM, rather than the direct effects of hrIL-7/HGFα on ETPs themselves.

Thus, although its precise mechanisms of action remain to be determined, our demonstration that hrIL-7/HGFα induces the rapid and complete regeneration of thymocytes and clonally diverse naïve T cells in vivo suggests that it may be useful clinically in correcting post-BMT T-cell deficiency and its complications. This is especially true, because as the hrIL-7/HGFα was generated in a mammalian expression system and seems to be glycosolated. Indeed, if hrIL-7/HGFα exhibits the same ability as mrIL-7/HGFβ to generate hematopoeitic stem cells, to enhance hematopoeitic stem-cell implantation in BM, and to support long-term hematopoietic reconstitution (L. Lai and I. Goldschneider, manuscript in preparation), it might prove to be a useful adjunct for improving the success rate of BMT itself.

Back to Top | Article Outline

MATERIALS AND METHODS

Mice

Four- to 8-week-old C57BL/6 (B6) and B6 Ly5.1 mice were purchased from the National Cancer Institute (Frederick, MD). Mice were housed, treated, and handled in accordance with the guidelines set forth by the University of Connecticut Health Center Animal Care Committee.

Back to Top | Article Outline

Construction, Expression, and Purification of Human Single-Chain IL-7/HGFα Hybrid Cytokine

The human IL-7/HGFα gene was constructed by adapting the protocol that we previously used to construct the murine IL-7/HGFβ gene (6). Briefly, human IL-7 cDNA was amplified with primers A and B (see Table, SDC 1,http://links.lww.com/TP/A471) and human cDNA for the NK1 splice variant of HGFα with primer C and D. The polymerase chain reaction (PCR) products of IL-7 and NK1 were combined and subjected to an additional round of PCR with primers A and D. Because primers B and C contained the linker sequence encoding (Gly4Ser)2, the IL-7/HGFα gene was constructed after the overlap extension PCR. The IL-7/HGFα gene was then cloned into a pOptiVEC mammalian expression vector (Invitrogen, Carlsbad, CA) and transfected into Chinese hamster ovary cell-derived DG44 cells (Invitrogen). The hrIL-7/HGFα protein was then purified from the supernatant, as we described previously (6). Briefly, the supernatant was concentrated by a prep/scale–tangential flow filter cartridge with 10 kDa MW cutoff (Millipore, Bedford, MA) and diafiltered into washing buffer. The sample was then applied to serially linked columns of DEAE and CM sepharose (GE Health Care Biosciences, Piscataway, NJ). After washing, the linked columns were separated, and protein was eluted from the CM column in the washing buffer containing NaCl gradient. The purified protein was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, Western blotting using antibodies against both human IL-7 and HGF, and in vitro thymocyte-stimulatory activity (6). For controls, we also cloned and expressed human IL-7 (using primers A and E) and HGFα (NK1) (using primers F and G) genes individually and purified hrIL-7 and hrHGFα proteins from the expression system, respectively.

Back to Top | Article Outline

BMT Procedure

BM was obtained from mouse femurs and tibias and T-cell depletion by immunomagnetic removal of the CD4+ CD8+ Thy-1.2+ cells as described (28). Recipients (B6 mice) received 1000 cGy total body irradiation and were injected IV 2 to 4 hours later with 2×106 TCD-BM cells from congeneic (B6 Ly5.1) mice. Groups of mice were then injected intraperitoneally with hrIL-7/HGFβ, hrIL-7/HGFα, hrIL-7, and hrHGFα or PBS at 2-day intervals between days 1 and 25 after BMT. Some hrHGFα-treated BMT mice were also injected IV with 50 μg anti-c-Met antibody (R&D Systems, Minneapolis, MN) and 450 μg anti-IL-7Rα antibody (A7R34), or isotype control on the day of BMT and once per week thereafter. The A7R34 hybridoma (anti-IL-7Rα) was generated by S. Nishikawa (see Ref. 29, Kumamoto University School of Medicine, Kumamoto, Japan); We obtained the hybridoma from Dr. I. Weissman (Stanford University School of Medicine) and purified the antibody as described (30).

Back to Top | Article Outline

Flow Immunocytometry

TECs were isolated as per Gray et al. (31). Single-cell suspensions of thymocytes and spleen cells were stained with one or more of the following fluorochrome-conjugated antibodies as described (6): CD4, CD8, CD25, CD44, CD62L, CD117, CD127, BP-1, EpCAM, CD45, I-Ab, CD45.1, and a TCR Vβ antibody panel. ETPs were identified as lin IL-7Rα (CD127) c-kit+ (CD117) CD44+ CD25 thymus cells. A cocktail of antibodies against TER-119, B220, CD19, IgM, Gr-1, CD11b, CD11c, NK1.1, TCRβ, CD3e, and CD8α was used to distinguish the lin cells. The samples were analyzed on a FACSCalibur flow cytometer (Becton and Dickinson, San Jose, CA) with CellQuest acquisition software. Data analysis was done using FlowJo software (Ashland, OR).

Back to Top | Article Outline

Confocal Microscopy

Purified CD4 CD8 DN thymocytes were washed, and stimulated with either hrIL-7/HGFα (60 ng/mL) or the combination of hrIL-7 (24 ng/mL) and hrHGFβ (36 ng/mL) for 2 hr in serum-free medium. The cells were prepared by cytospin, fixed by 4% paraformaldehyde, and stained with fluorescein isothiocyanate -labeled rat anti-IL-7Rα antibody and purified goat anti-c-Met antibody developed with Alexa fluor-594-labeled anti-goat IgG as we described previously (6). The cells were then observed under a Zeiss LSM510 Meta laser scanning confocal microscope (Carl Zeiss, Thornwood, NY).

Back to Top | Article Outline

Statistical Analysis of Data

The values of P were based on two-sided Student's t test. A confidence level above 95% (P<0.05) was determined as significant.

Back to Top | Article Outline

REFERENCES

1. Williams KM, Hakim FT, Gress RE. T cell immune reconstitution following lymphodepletion. Semin Immunol 2007; 19: 318.
2. van den Brink MR, Alpdogan O, Boyd RL. Strategies to enhance T cell reconstitution in immunocompromised patients. Nat Rev Immunol 2004; 4: 856.
3. McKenna SD, Chen F, Lai L, et al. Identification of an IL-7-associated pre-pro-B cell growth-stimulating factor (PPBSF). I. Production of the non-IL-7 component by bone marrow stromal cells from IL-7 gene-deleted mice. J Immunol 1998; 160: 2272.
4. Lai L, Chen F, McKenna S, et al. Identification of an IL-7-associated pre-pro-B cell growth-stimulating factor (PPBSF). II. PPBSF is a covalently linked heterodimer of IL-7 and a Mr 30,000 co-factor. J Immunol 1998; 160: 2280.
5. Lai L, Goldschneider I. Cutting edge: Identification of a hybrid cytokine consisting of Interleukin-7 and the β-chain of the heptocyte growth factor/scatter factor. J Immunol 2001; 167: 3550.
6. Lai L, Zeff RA, Goldschneider I. A recombinant single-chain IL-7/HGFβ hybrid cytokine induces juxtacrine interactions of the IL-7 and HGF (c-Met) receptors and stimulates the proliferation of CFU-S12, CLPs, and pre-pro-B cells. Blood 2006; 107: 1776.
7. Jin J, Goldschneider I, Lai L. In vivo administration of the rIL-7/HGFβ hybrid cytokine efficiently restores the thymopoiesis and naïve T cell generation in lethally-irradiated mice after syngeneic bone marrow transplantation. J Immunol 2011; 186: 1915.
8. Goodwin RG, Lupton S, Schmierer A, et al. Human interleukin 7: Molecular cloning and growth factor activity on human and murine B-lineage cells. Proc Natl Acad Sci USA 1989; 86: 302.
9. Rubin JS, Bottaro DP, Aaronson SA. Hepatocyte growth factor/scatter factor and its receptor the c-met proto-oncogene product. Biophysica Acta 1993; 1155: 357.
10. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: From hepatopoiesis to hematopoiesis. J Cell Biol 1995; 129: 1177.
11. Cioce V, Csaky KG, Chan AML, et al. Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity. J Biol Chem 1996; 271: 13110.
12. Allman D, Sambandam A, Kim S, et al. Thymopoiesis independent of common lymphoid progenitors. Nat Immunol 2003; 4: 168.
13. Bhandoola A, von Boehmer H, Petrie HT, et al. Commitment and developmental potential of extrathymic and intrathymic T cell precursors: Plenty to choose from. Immunity 2007; 26: 678.
14. Porritt HE, Rumfelt LL, Tabrizifard S, et al. Heterogeneity among DN1 prothymocytes reveals multiple progenitors with different capacities to generate T cell and non-T cell lineages. Immunity 2004; 20: 735.
15. Anderson G, Jenkinson WE, Jones T, et al. Establishment and functioning of intrathymic microenvironments. Immunol Rev 2006; 209: 10.
16. Chidgey A, Dudakov J, Seach N, et al. Impact of niche aging on thymic regeneration and immune reconstitution. Semin Immunol 2007; 19: 331.
17. Kelly RM, Goren EM, Taylor PA, et al. Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation. Blood 2010; 115: 1088.
18. Min D, Taylor PA, Panoskaltsis-Mortari A, et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: A new approach to improve thymic and peripheral T cell reconstitution after bone marrow transplantation. Blood 2002; 99: 4592.
19. Imado T, Iwasaki T, Kataoka Y, et al. Hepatocyte growth factor preserves graft-versus-leukemia effect and T cell reconstitution after marrow transplantation. Blood 2004; 104: 1542.
20. Carrio R, Altman NH, Lopez DM. Downregulation of interleukin-7 and hepatocyte growth factor in the thymic microenvironment is associated with thymus involution in tumor-bearing mice. Cancer Immunol Immunother 2009; 58: 2059.
21. Lokker NA, Godowski PJ. Generation and characterization of a competitive antagonist of human hepatocyte growth factor, HGF/NK1. J Biol Chem 1993; 268: 17145.
22. Jakubczak JL, LaRochelle WJ, Merlino G. NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo. Mol Cell Biol 1998; 18: 1275.
23. Capitini CM, Chisti AA, Mackall CL. Modulating T cell homeostasis with IL-7: preclinical and clinical studies. J Intern Med 2009; 266: 141.
24. Van De, Wiele CJ, Marino JH, et al. Thymocytes between the (beta)-selection and positive selection checkpoints are nonresponsive to IL-7 as assessed by STAT-5 phosphorylation. J Immunol 2004; 172: 4235.
25. Cosenza L, Gorgun G, Urbano A, et al. Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cell Signal 2002; 14: 317.
26. Klug DB, Carter C, Crouch E, et al. Interdependence of cortical thymic epithelial cell differentiation and T-lineage commitment. Proc Natl Acad Sci USA 1998; 95: 11822.
27. Manley NR. Thymus organogenesis and molecular mechanisms of thymic epithelial cell differentiation. Semin Immunol 2000; 12: 421.
28. Lai L, Jin J. Generation of thymic epithelial cell progenitors by mouse embryonic stem cells. Stem cells 2009; 27: 3012.
29. Sudo TS, Nishikawa N, Ohno N, et al. Expression and function of the interleukin 7 receptor in murine lymphocytes. Proc Natl Acad Sci USA 1993; 90: 9125.
30. Lenz DC, Kurz, SK, Lemmens E, et al. IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory. Proc Natl Acad Sci USA 2004; 101: 9357.
31. Gray DH, Chidgey AP, Boyd RL. Analysis of thymic stromal cell populations using flow cytometry. J Immunol Methods 2002; 260: 15.
Keywords:

Bone marrow transplantation; T-cell regeneration; Thymus; Cytokine

Supplemental Digital Content

Back to Top | Article Outline
© 2011 Lippincott Williams & Wilkins, Inc.